Dr. Amalfitano, DO, PhD, is the Director of the MSU-Clinical and Translational Sciences Institute, which seeks to support clinical and translational research efforts being conducted at MSU. He is also a Board Certified Clinical Geneticist, and is also trained as a classical research scientist. In his clinical practice, he routinely identifies patients with various types of genetic diseases, and not only provides for advanced forms of genetic testing, but also provides specific therapies for rare conditions including Pompe Disease, Fabry Disease, Gaucher Disease, and some of the Mucopolysaccharidoses. He also provides supportive therapy and important insights relative to a large number of complex genetic diseases, such as Marfan Syndrome, forms of muscular dystrophy, and Neurofibromatosis. Dr. Amalfitano has also participated as a leader at most levels of clinical translational research, including "first in man" studies. Those pivotal studies directly led to expanded clinical trials, and FDA approval of the drug "Myozyme", a drug that is now routinely prescribed for Pompe patients world-wide. Complementing this expertise, Dr. Amalfitano also directs a state of the art biomedical research laboratory, the focus of which is upon human genetics, gene transfer based technology development, as well analyzing interactions of genes and gene transfer vectors with the human immune system. Some of the gene transfer technologies developed and patented by Dr. Amalfitano have provided a foundation for biotechnology start up ventures, one of which has led to entry of these technologies into Phase II clinical trials testing in the United States. Dr. Amalfitano's research efforts have been routinely supported by NIH grants, as well as private foundations and corporate sponsors. Together, this background provides a unique expertise to the Advisory Board of the MSU-Sparrow Innovation Center.
Please visit the College of Osteopathic Medicine website for more information on Dr. Amalfitano.